



(12) Translation of  
European patent specification

(11) NO/EP 2794654 B1

NORWAY

(19) NO  
(51) Int Cl.  
**C07K 16/00 (2006.01)**  
**A61K 39/00 (2006.01)**  
**C07K 16/18 (2006.01)**

**Norwegian Industrial Property Office**

---

(21) Translation Published 2019.08.19

(80) Date of The European Patent Office Publication of the Granted Patent 2019.05.22

(86) European Application Nr. 12859920.6

(86) European Filing Date 2012.12.19

(87) The European Application's Publication Date 2014.10.29

(30) Priority 2011.12.20, US, 201161577817 P

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

(73) Proprietor Janssen Biotech, Inc., 800/850 Ridgeview Drive, Horsham, PA 19044, USA

(72) Inventor ALDERFER, Christopher, 1400 McKean Road, Spring House, PA 19477, USA  
JANECKI, Dariusz, Kastelsvej 19 ST TH, 2100 Kobenhaven O, Danmark  
LIU, Xuesong, 1400 McKean Road, Spring House, PA 19477, USA  
MURDOCK, Melissa, 1400 McKean Road, Spring House, PA 19477, USA  
WU, Sheng-Jiun, 1400 McKean Road, Spring House, PA 19477, USA  
MERCKEN, Marc, Turnhoutseweg 30, B-2340 Beerse, Belgia  
VANDERMEEREN, Marc, Turnhoutseweg 30, B-2340 Beerse, Belgia  
MALIA, Thomas, 1400 McKean Road, Spring House, PA 19477, USA

(74) Agent or Attorney OSLO PATENTKONTOR AS, Postboks 7007 M, 0306 OSLO, Norge

---

(54) Title **ANTI-PHF-TAU ANTIBODIES AND THEIR USES**

(56) References Cited:  
US-A1- 2011 077 224  
US-A1- 2012 276 009  
US-A1- 2011 118 299  
US-A1- 2011 059 093  
US-A1- 2009 142 261  
WO-A2-2010/144711  
US-A9- 2011 143 443  
WO-A1-93/08302  
US-A1- 2009 169 547  
US-A1- 2007 048 785

WO-A1-2009/017161

WO-A1-95/17429

US-A1- 2012 087 861

WO-A1-96/04309

JEAN-PIERRE BRION ET AL: "Neurofilament Monoclonal Antibodies RT97 and 8D8 Recognize Different Modified Epitopes in Paired Helical Filament-? in Alzheimer's Disease", JOURNAL OF NEUROCHEMISTRY, vol. 60, no. 4, 1 April 1993 (1993-04-01), pages 1372-1382, XP55207252, NEW YORK, NY, US ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.1993.tb03298.x

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 30 October 1995 (1995-10-30), KSIEZAK-REDING H ET AL: "Binding of Alz 50 depends on Phe8 in tau synthetic peptides and varies between native and denatured tau proteins.", Database accession no.

NLM8593596 & KSIEZAK-REDING H ET AL: "Binding of Alz 50 depends on Phe8 in tau synthetic peptides and varies between native and denatured tau proteins.", BRAIN RESEARCH 30 OCT 1995, vol. 697, no. 1-2, 30 October 1995 (1995-10-30), pages 63-75, ISSN: 0006-8993

MERCKEN ET AL.: 'Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes.' ACTA NEUROPATHOL. vol. 84, no. 3, 1992, pages 265 - 272, XP008049337

PORZIG R ET AL: "Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 358, no. 2, 29 June 2007 (2007-06-29) , pages 644-649, XP026422493, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.04.187 [retrieved on 2007-06-29]

JICHA GREGORY A ET AL: "A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease", JOURNAL OF NEUROCHEMISTRY, vol. 69, no. 5, 1997, pages 2087-2095, XP002743263, ISSN: 0022-3042

GOEDERT M ET AL: "EPITOPE MAPPING OF MONOCLONAL ANTIBODIES TO THE PAIRED HELICAL FILAMENTS OF ALZHEIMER'S DISEASE: IDENTIFICATION OF PHOSPHORYLATIONSITES IN TAU PROTEIN", BIOCHEMICAL JOURNAL, PORTLAND PRESS LTD, GB, vol. 301, no. PART 03, 1 August 1994 (1994-08-01), pages 871-877, XP000996679, ISSN: 0264-6021

MALIA THOMAS J ET AL: "Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8", PROTEINS STRUCTURE FUNCTION AND BIOINFORMATICS, vol. 84, no. 4, April 2016 (2016-04), pages 427-434, ISSN: 0887-3585(print)

FRANCK R. PETRY ET AL: "Specificity of Anti-Tau Antibodies when Analyzing Mice Models of Alzheimer's Disease: Problems and Solutions", PLOS ONE, vol. 9, no. 5, 2 May 2014 (2014-05-02), page e94251, XP055207209, DOI: 10.1371/journal.pone.0094251

SINGER D ET AL: "Neighbored phosphorylation sites as PHF-tau specific markers in Alzheimer's disease", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 346, no. 3, 4 August 2006 (2006-08-04), pages 819-828, XP024925390, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2006.05.201 [retrieved on 2006-08-04]

HOFFMANN R ET AL: "Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 36, no. 26, 1 July 1997 (1997-07-01), pages 8114-8124, XP002625812, ISSN: 0006-2960, DOI: 10.1021/BI970380+

CONDAMINES O ET AL: "New immunoassay for the mapping of neurofibrillary degeneration in Alzheimer's disease using two monoclonal antibodies against human paired helical filament tau proteins", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 192, no. 2, 9 June 1995 (1995-06-09), pages 81-84, XP002266004, ISSN: 0304-3940, DOI: 10.1016/0304-3940(95)11617-6

MASATO HASEGAWA ET AL: "Characterization of Two Distinct Monoclonal Antibodies to Paired Helical Filaments: Further Evidence for Fetal-Type Phosphorylation of the ? in Paired Helical Filaments", JOURNAL OF NEUROCHEMISTRY, vol. 60, no. 6, 1 June 1993 (1993-06-01), pages 2068-2077, XP55207251, NEW YORK, NY, US ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.1993.tb03491.x

HASEGAWA M ET AL: "CHARACTERIZATION OF MAB AP422, A NOVEL PHOSPHORYLATION-DEPENDENT MONOCLONAL ANTIBODY AGAINST TAU PROTEIN", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 384, 1 January 1996 (1996-01-01), pages 25-30, XP000916614, ISSN: 0014-5793, DOI: 10.1016/0014-5793(96)00271-2

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**Patentkrav**

1. Isolert antistoff som binder PHF -tau som omfatter en VH av SEQ ID NO: 37 og en VL av SEQ ID NO: 38 eller en humanisert versjon derav,  
  
hvor nevnte humaniserte versjonen har affinitet mot PHF-tau med en  
5 dissosiasjonskonstant (KD) mindre enn eller lik 10<sup>-10</sup> M, som bestemt av ProteOn.
2. Isolert antistoff ifølge krav 1, hvor antistoffet er av IgG-isotype, eventuelt hvor antistoffet er av:
  - (a) IgG1 isotype,
  - (b) IgG2 isotype,
  - 10 (c) IgG3 isotype, eller
  - (d) IgG4 isotype.
3. Isolert antistoff ifølge krav 1 eller 2, hvor antistoffet er et antistofffragment, så som et Fab, Fab', F(ab')<sub>2</sub> eller Fv fragment.
4. Isolert antistoff ifølge et hvilket som helst av kravene 1-3, hvor antistoffet er  
15 humanisert.
5. Isolert polynukleotid som koder for isolert antistoff ifølge et hvilket som helst av kravene 1-4.
6. Vektor omfattende et polynukleotid ifølge krav 5.
7. Vertscelle omfattende vektoren ifølge krav 6.
- 20 8. Fremgangsmåte for fremstilling av et antistoff som binder PHF-tau omfattende dyrkning av vertscellen ifølge krav 7 og utvinning av antistoffet fremstilt av vertscellen.
9. Farmasøytisk sammensetning omfattende antistoff ifølge et hvilket som helst av kravene 1-4 og en farmasøytisk akseptabel bærer.
- 25 10. Isolert antistoff ifølge et hvilket som helst av kravene 1-4 for anvendelse i terapi.

11. Isolert antistoff ifølge et hvilket som helst av kravene 1-4 for anvendelse i behandling eller forebygging eller reduksjon av symptomene på en neurodegenerativ sykdom som involverer patologisk aggregering av tau i hjernen.
12. Isolert antistoff til anvendelse ifølge krav 11, hvor den neurodegenerative sykdommen er Alzheimers sykdom.

5